Development and preclinical evaluation of a trivalent, formalin-inactivated Shigella whole-cell vaccine

R. W. Kaminski, M. Wu, K. R. Turbyfill, K. Clarkson, B. Tai, A. L. Bourgeois, L. L. Van De Verg, R. I. Walker, E. V. Oaks

Research output: Contribution to journalArticle

Abstract

Studies were undertaken to manufacture a multivalent Shigella inactivated whole-cell vaccine that is safe, effective, and inexpensive. By using several formalin concentrations, temperatures, and incubation periods, an optimized set of inactivation conditions was established for Shigella flexneri 2a, S. sonnei, and S. flexneri 3a to produce inactivated whole cells expressing a full repertoire of Ipa proteins and lipopolysaccharide (LPS). The inactivation conditions selected were treatment with 0.2% formalin (S. flexneri 2a and 3a) or 0.6% formalin (S. sonnei) for 48 h at 25°C. Vaccine formulations prepared under different inactivation conditions, in different doses (10E5, 10E7, and 10E9 cells), and with or without the inclusion of double-mutant heat-labile toxin (dmLT) were evaluated in mice. Two intranasal immunizations with ≥10E7 inactivated whole cells resulted in high levels of anti-Invaplex and moderate levels of LPS-specific IgG and IgA in serum and in lung and intestinal wash samples. Addition of dmLT to the vaccine formulations did not significantly enhance humoral immunogenicity. Minimal humoral responses for IpaB, IpaC, or IpaD were detected after immunization with inactivated whole Shigella cells regardless of the vaccine inactivation conditions. In guinea pigs, monovalent formulations of S. flexneri 2a of 3a or S. sonnei consisting of 10E8, 10E9, or 10E10 cells were protective in a keratoconjunctivitis assay. A trivalent formulation provided protection against all three serotypes (S. flexneri 2a, P = 0.018; S. flexneri 3a, P = 0.04; S. sonnei, P < 0.0001). The inactivated Shigella whole-cell vaccine approach incorporates an uncomplicated manufacturing process that is compatible with multivalency and the future development of a broadly protective Shigella vaccine.

Original languageEnglish (US)
Pages (from-to)366-382
Number of pages17
JournalClinical and Vaccine Immunology
Volume21
Issue number3
DOIs
StatePublished - Mar 2014
Externally publishedYes

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Clinical Biochemistry
  • Microbiology (medical)

Fingerprint Dive into the research topics of 'Development and preclinical evaluation of a trivalent, formalin-inactivated Shigella whole-cell vaccine'. Together they form a unique fingerprint.

  • Cite this

    Kaminski, R. W., Wu, M., Turbyfill, K. R., Clarkson, K., Tai, B., Bourgeois, A. L., Van De Verg, L. L., Walker, R. I., & Oaks, E. V. (2014). Development and preclinical evaluation of a trivalent, formalin-inactivated Shigella whole-cell vaccine. Clinical and Vaccine Immunology, 21(3), 366-382. https://doi.org/10.1128/CVI.00683-13